Search results
2 days ago · Source Reference: Cutolo M, et al "Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis" Lancet Rheumatol 2024; DOI: 10.1016/S2665-9913(24)00243-1.
3 days ago · The management of GERD in systemic sclerosis incorporates pharmacological therapy and lifestyle modifications. Patients are advised to elevate the head of the bed, avoid going to bed for 3–4 h following a meal, lose weight, stop smoking and minimize alcohol use.
4 days ago · Traditionally, in people with primary Raynaud's phenomenon, exposure to cold temperatures triggers episodes of vasospasm, primarily due to an abnormal reaction of the sympathetic nervous system.1 This mechanism is particularly pronounced in Raynaud's phenomenon secondary to systemic sclerosis, where the underlying vasculopathy and related fibrosis can further compromise blood flow in ...
2 days ago · Describe the clinical characteristics of scleroderma patients that place them at high risk of developing PAH. Devise strategies to optimize screening and early detection of PAH in scleroderma patients. Develop best management practices to improve the care of patients with scleroderma-related PAH.
- Scientific Director, Medscape, LLC
4 days ago · Purpose of review: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The American College of Rheumatology (ACR), in conjunction with the American College of Chest Physicians (CHEST), recently published clinical practice guidelines for the treatment ...
13 hours ago · Objective Raynaud phenomenon (RP) and digital ulcers (DUs) are the main signs of digital vasculopathy in systemic sclerosis (SSc). Selexipag is an oral prostacyclin agonist approved for SSc-related pulmonary arterial hypertension. Following our previous preliminary short-course report, we herein present long-term data on selexipag safety and efficacy in the treatment of SSc digital ...
3 days ago · While gastroesophageal reflux disease (GERD) treatment does not influence the development or severity of interstitial lung disease (ILD), aggressive treatment with combined proton pump inhibitor (PPI) and histamine 2 receptor antagonist (H2RA) therapy may improve survival among patients with systemic sclerosis (SSc)-ILD, according to study results published in Arthritis Research & Therapy.
